Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of 4-Chloromethyl-5-methyl-1,3-dioxol-2-one, (DMDO-Cl) (CAS: 80841-78-7) with high quality, commercial production. We can provide COA, worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com
| Chemical Name |
4-Chloromethyl-5-methyl-1,3-dioxol-2-one |
| Synonyms |
DMDO-Cl |
| CAS Number |
80841-78-7 |
| CAT Number |
RF-PI1871 |
| Stock Status |
In Stock, Production Capacity 300 Tons/Year |
| Molecular Formula |
C5H5ClO3 |
| Molecular Weight |
148.54 |
| Boiling Point |
93℃/2 mmHg |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
Colorless to Yellow Liquid |
| Identification (GC) |
The retention time of the major peak in the chromatogram of the sample corresponds ti that of the standard as obtained in purity and related substances |
| Purity / Analysis Method |
>96.0% (GC) |
| Water (by Karl Fischer) |
<0.50% |
| Impurity A |
<1.50% |
| Impurity B |
<0.50% |
| Impurity C |
<3.00% |
| Impurity D |
<4.00% |
| Impurity E |
<0.10% |
| Refractive Index N20/D |
1.476~1.482 |
| Specific Gravity (20/20℃) |
1.357~1.363 |
| Proton NMR Spectrum |
Conforms to Structure |
| Test Standard |
Enterprise Standard |
| Usage |
Intermediate of Olmesartan Medoxomil (CAS: 144689-63-4)
|
Route of Synthesis of 4-Chloromethyl-5-methyl-1,3-dioxol-2-one
Package: Fluorinated Bottle, 25kg/Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
4-Chloromethyl-5-methyl-1,3-dioxol-2-one, (DMDO-Cl) (CAS: 80841-78-7) is an intermediate of Olmesartan Medoxomil (CAS: 144689-63-4. Olmesartan Medoxomil is a new selective and competitive nonpeptide angiotensin II receptor antagonist used to treat high blood pressure. Olmesartan works by blocking the binding of angiotensin II to the AT1 receptors in vascular muscle. By blocking the binding rather than the synthesis of angiotensin II, olmesartan inhibits the negative regulatory feedback on renin secretion. Olmesartan Medoxomil was launched in the US as Benicar@, an orally administered treatment for hypertension.
